>
Fa   |   Ar   |   En
   cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis  
   
نویسنده connell nathan t. ,connors jean m.
منبع journal of thrombosis and thrombolysis - 2019 - دوره : 48 - شماره : 3 - صفحه:382 -386
چکیده    Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome. the direct oral anticoagulant edoxaban has been shown to be noninferior to dalteparin for the treatment of cancer-associated thrombosis. in a markov simulation model, edoxaban with 6-month time horizon and a united states societal perspective with 2017 us dollars, edoxaban was the preferred strategy in the general cancer population (6-month cost $6061 with 0.34 quality adjusted life years) and in a subgroup of patients with gastrointestinal malignancy (6-month cost $7227 with 0.34 quality adjusted life years). the incremental cost effectiveness ratio of dalteparin compared to edoxaban was $1,873,535 in the general oncology population and $694,058 in the gastrointestinal malignancy population.
کلیدواژه cost-effectiveness ,edoxaban ,dalteparin ,cancer-associated thrombosis ,venous thromboembolism
آدرس brigham and women’s hospital, hematology division, usa. harvard medical school, usa, brigham and women’s hospital, hematology division, usa. harvard medical school, usa
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved